最近一个月来，权识国际累计涨幅22.22%，今年来累计跌幅58.33%，跑输恒生指数17.51%的涨幅。 财务数据显示，截至2024年12月31日，权识国际实现营业总收入3.58亿元，同比增长0.71%；归母净利 润-7836.71万元，同比减少327.41%；毛利率36.64%，资产负债率51.84%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，家庭电器及用品行业市盈率（TTM）平均值为13.64倍，行业中值3.61倍。权识国际市 盈率-5.13倍，行业排名第61位；其他凯富善集团控股（08512.HK）为1.58倍、丽年国际（09918.HK） 为1.63倍、华讯（00833.HK）为3.26倍、盛诺集团（01418.HK）为3.61倍、旷世芳香（01925.HK）为 3.83倍。 资料显示，权识国际集团股份有限公司于1991年成立,并成功于2001年在香港交易所主板上市,股份代号 00381。侨雄国际以制造及销售礼品、玩具、旗帜及园艺产品等起家,客户遍布全球,包括迪士尼及华纳兄 弟等国际知名品牌。在运营实业的同时,公司一直在积极探索不同领域的投资机会,以拓宽本集团的业务 组合,加 ...

青海春天上述行为违反了《上市公司信息披露管理办法》(证监会令第40号)第二条、第四十八条和《上 市公司信息披露管理办法》(证监会令第182号)第三条、第四十一条的规定。青海春天董事长张雪峰， 实际控制人、时任董事肖融，财务总监王林，董事会秘书陈定对青海春天上述违规行为负有主要责任， 其中，张雪峰、王林、陈定违反了《上市公司信息披露管理办法》(证监会令第40号)第三条、第五十八 条和《上市公司信息披露管理办法》(证监会令第182号)第四条、第五十一条的规定;肖融违反了《上市 公司信息披露管理办法》(证监会令第40号)第三条、第四十八条和《上市公司信息披露管理办法》(证监 会令第182号)第四条、第四十一条的规定。 根据《上市公司信息披露管理办法》(证监会令第40号)第五十九条、《上市公司信息披露管理办法》(证 监会令第182号)第五十二条的规定，青海证监局决定对青海春天采取责令改正的行政监管措施，对张雪 峰、肖融、王林、陈定采取出具警示函的行政监管措施，并记入证券期货市场诚信档案。 经查，宜宾听花酒业发展有限责任公司(以下简称宜宾听花)为青海春天药用资源科技股份有限公司(以下 简称青海春天)酒水产品的生产商，青 ...

5月7日，截至港股收盘，恒生指数上涨0.13%，报22691.88点。权识国际（00381.HK）收报0.72港元/ 股，上涨46.94%，成交量552.96万股，成交额359.27万港元，振幅59.18%。 最近一个月来，权识国际累计跌幅12.5%，今年来累计跌幅62.88%，跑输恒生指数12.97%的涨幅。 财务数据显示，截至2024年12月31日，权识国际实现营业总收入3.58亿元，同比增长0.71%；归母净利 润-7836.71万元，同比减少327.41%；毛利率36.64%，资产负债率51.84%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 资料显示，权识国际集团股份有限公司于1991年成立,并成功于2001年在香港交易所主板上市,股份代号 00381。侨雄国际以制造及销售礼品、玩具、旗帜及园艺产品等起家,客户遍布全球,包括迪士尼及华纳兄 弟等国际知名品牌。在运营实业的同时,公司一直在积极探索不同领域的投资机会,以拓宽本集团的业务 组合,加强收入基础及综合实力。侨雄国际正处于向多元化发展转型的关键时期。2014年,公司成功收购 众乐发展有限公司28%的股权。众乐发展在中国江西省拥有1,76 ...

Financial Performance - The company reported revenue of approximately HKD 386.7 million for the fiscal year ending December 31, 2024, representing a 0.71% increase from HKD 383.9 million in 2023[4]. - The gross profit decreased to HKD 141.7 million, down 14.56% from HKD 165.8 million in the previous year[4]. - The loss attributable to shareholders was approximately HKD 84.6 million, a significant decline from a profit of HKD 37.2 million in 2023, marking a 327.41% decrease[6]. - The basic loss per share was HKD 24.83, compared to a profit of HKD 39.06 per share in the previous year, reflecting a 163.57% decline[6]. - The total comprehensive loss for the year was HKD 97,454,000, compared to a comprehensive income of HKD 52,431,000 in 2023[136]. - The net loss for the year was HKD 72,825,000, compared to a profit of HKD 65,701,000 in 2023, indicating a significant turnaround in performance[136]. Revenue Breakdown - The toy and gift business generated revenue of approximately HKD 239.7 million, down 8.7% from HKD 262.4 million in 2023, primarily due to decreased revenue from North America[13]. - The herbal medicine business generated revenue of approximately HKD 95,300,000, down from HKD 121,500,000 in 2023[21]. - The liquor business recorded revenue of approximately HKD 51,600,000, with no revenue reported in 2023[22]. - The group’s total revenue from North America was approximately HKD 239,000,000, a decrease from HKD 262,000,000 in 2023, accounting for 61.8% of total revenue[23]. - The group’s revenue from China was approximately HKD 147,700,000, up from HKD 122,100,000 in 2023, representing 38.2% of total revenue[23]. Assets and Liabilities - The total assets increased by 3.42% to HKD 796.6 million from HKD 770.3 million in 2023[4]. - The total equity rose by 12.85% to HKD 383.6 million, up from HKD 340.0 million in the previous year[4]. - The group’s cash and bank balances were approximately HKD 135,900,000 as of December 31, 2024, compared to HKD 111,900,000 in 2023[27]. - The group’s debt was approximately HKD 139,400,000 as of December 31, 2024, down from HKD 141,800,000 in 2023[27]. - The group’s capital debt ratio improved to 68% from 89.1% in the previous year[27]. - The group had net current liabilities of approximately HKD 26,428,000 as of December 31, 2024[108]. Operational Efficiency - Administrative expenses decreased by approximately 3.9% to about HKD 83,000,000 from HKD 86,400,000 in the previous year[25]. - Financial costs increased by approximately 6.8% to HKD 28,900,000 from HKD 27,100,000 in the previous year[26]. - The operating cash flow for the year was a net outflow of HKD 3,374,000, a decrease from a net inflow of HKD 27,543,000 in 2023[143]. - The company experienced a loss before tax of HKD 65,844,000, contrasting with a profit of HKD 69,074,000 in the prior year[143]. Corporate Governance - The company is committed to achieving excellence in corporate governance and has complied with all applicable code provisions, except for a specific deviation noted[89]. - The board of directors consists of five executive directors, one non-executive director, and three independent non-executive directors as of December 31, 2024[92]. - The board held seven meetings in 2024 to review financial and operational performance and make important decisions[94]. - The remuneration committee reviewed the remuneration policy and approved the compensation for directors and senior management during the year[98]. Investment and Diversification - The company has initiated a liquor trading business as part of its diversification strategy to ensure long-term development[10]. - The company is exploring other profitable investment opportunities to expand its existing business and diversify its revenue base[9]. - The company is involved in various business investments, including leisure and cultural sectors, indicating a diversified investment strategy[147]. Shareholder Information - The board does not recommend any final dividend for the year ended December 31, 2024[32]. - The company has not purchased, redeemed, or sold any of its listed securities during the year ended December 31, 2024[33]. - Sales to the top five customers accounted for approximately 64.42% of total revenue, with the largest customer contributing about 31.87%[58]. - Purchases from the top five suppliers represented approximately 57.66% of total procurement, with the largest supplier accounting for about 21.74%[58]. Compliance and Risk Management - The company has no significant contingent liabilities as of December 31, 2024, and December 31, 2023[30]. - There are no major capital commitments reported as of December 31, 2024, and December 31, 2023[31]. - The group has engaged MOSS Valuation & Advisory Limited as an independent consultant to review its internal control systems, focusing on financial, operational, compliance, and risk management functions[112]. - The group has adopted a risk management framework that includes identifying significant risks and assessing their impact on the business[115]. Audit and Financial Reporting - The independent auditor confirmed that the consolidated financial statements fairly reflect the group's financial position as of December 31, 2024[117]. - The audit committee is responsible for overseeing the financial reporting process of the company[129]. - The auditor identified significant risks related to material misstatements due to fraud or error during the audit process[131]. - The consolidated financial statements are prepared on a going concern basis, contingent on the successful implementation of the board's plans[157].

Financial Performance - Total revenue for the year ending December 31, 2024, was HKD 386,662,000, representing a slight increase from HKD 383,923,000 in the previous year[3]. - Gross profit decreased to HKD 141,666,000 from HKD 165,807,000, indicating a decline of approximately 14.6%[3]. - The company reported a net loss attributable to shareholders of HKD 84,626,000 compared to a profit of HKD 37,213,000 in the previous year[3]. - Basic loss per share was HKD 24.83, compared to earnings per share of HKD 39.06 in the prior year[3]. - The company experienced a net loss of HKD 72,825,000 for the year, compared to a loss of HKD 65,701,000 in the previous year[4]. - The company reported a loss of HKD 84,626,000 for the year ending December 31, 2024, compared to a profit of HKD 37,213,000 for the year ending December 31, 2023[40]. - The basic and diluted loss per share for 2024 was HKD (24.83), while for 2023 it was HKD 39.06[40]. - The company reported a significant impairment loss of HKD 35,814,000 related to investments in joint ventures[29]. Revenue Breakdown - Revenue from toy and gift sales reached HKD 239,744,000 in 2024, a decrease of 8.6% from HKD 262,377,000 in 2023[21]. - Revenue from herbal products was HKD 95,286,000 in 2024, down 21.6% from HKD 121,546,000 in 2023[21]. - Revenue from traditional Chinese medicine business was approximately HKD 95,300,000 this year, down from HKD 121,500,000 in 2023[76]. - Revenue from toys and gifts was HKD 123,231,000 in 2024, compared to HKD 98,818,000 in 2023, reflecting a growth of 24.6%[32]. - Revenue from Chinese herbal medicine was HKD 57,003,000 in 2024, compared to HKD 76,442,000 in 2023, indicating a decline of 25.5%[33]. - Revenue from external customers for the year ended December 31, 2024, was HKD 386,662,000, compared to HKD 383,923,000 for the year ended December 31, 2023, representing a slight increase of 0.6%[26]. Expenses and Costs - Administrative expenses were HKD 82,964,000, down from HKD 86,381,000, reflecting a reduction of about 3.8%[3]. - Total cost of sales increased to HKD 244,996,000 from HKD 218,116,000, marking an increase of about 12.3%[3]. - The cost of sales increased to HKD 190,861,000 in 2024 from HKD 164,500,000 in 2023, reflecting a rise of about 15.9%[40]. - Research and development costs rose to HKD 6,258,000 in 2024, compared to HKD 5,429,000 in 2023, indicating an increase of approximately 15.3%[40]. - The company reported a significant increase in sales and distribution costs, which rose to HKD 36,171,000 in 2024 from HKD 37,346,000 in 2023[40]. - Financial costs increased by approximately 6.8% to HKD 28,900,000 from HKD 27,100,000 in 2023[82]. Assets and Liabilities - Non-current assets amounted to HKD 463,631,000, an increase from HKD 454,819,000 in the previous year[5]. - Current assets increased to HKD 332,980,000 from HKD 315,462,000 year-over-year[5]. - The company’s total liabilities increased to HKD 359,408,000 from HKD 277,349,000 in the previous year[5]. - The company’s total assets decreased to HKD 437,203,000 from HKD 492,932,000 year-over-year[5]. - The group reported a loss of approximately HKD 72,825,000 for the year ending December 31, 2024, and is in a net current liability position of about HKD 26,428,000[97]. - Total liabilities as of December 31, 2024, were HKD 412,962,000, a decrease from HKD 430,305,000 as of December 31, 2023, indicating a reduction of about 4.0%[28]. Strategic Plans and Outlook - The company plans to focus on market expansion and new product development in the upcoming fiscal year[3]. - Future guidance indicates a cautious outlook due to current market conditions and operational challenges[3]. - The company plans to expand its market presence and invest in new product development to drive future growth[32]. - The group is currently evaluating the impact of delayed construction schedules for high-end hotels and villas, expected to commence in October 2025[69]. Corporate Governance and Compliance - The company has complied with all applicable corporate governance code provisions, except for a specific provision regarding the attendance of independent non-executive directors at the annual general meeting[98][99]. - The Audit Committee has reviewed the annual performance report for the year ending December 31, 2024[101]. - The company's annual report will be sent to shareholders and published on the stock exchange and the company's website at an appropriate time[102]. Share Capital and Equity - The company changed its name from "Kiu Hung International Holdings Limited" to "AOM International Group Company Limited" effective November 8, 2024[8]. - The company completed a share consolidation on April 28, 2023, reducing the total number of ordinary shares owed to Mr. Guo from 800,000 to 160,000 shares[56]. - The company completed another share consolidation on January 18, 2024, further reducing the total number of ordinary shares owed to Mr. Guo from 160,000 to 80,000 shares[56]. - The company issued 80,000,000 shares at HKD 0.10 each on May 21, 2019, as part of a debt settlement of HKD 17,600,000[55]. Employee and Operational Metrics - The group employed 321 employees as of December 31, 2024, down from 387 employees in 2023[93].

Financial Performance - The group recorded a revenue of approximately HKD 143.4 million for the six months ended June 30, 2024, a decrease of about 6% compared to HKD 152.9 million in the same period last year[5]. - Profit attributable to equity holders of the company was approximately HKD 17.6 million, down from HKD 36.4 million in the previous year, primarily due to losses from the fruit planting business and reduced income from the issuance of ordinary shares to settle financial liabilities[5]. - The basic earnings per share for the period was HKD 0.1854, compared to HKD 0.3921 (restated) in the previous year[5]. - Revenue for the six months ended June 30, 2024, was HKD 143,434,000, a decrease of 6.5% compared to HKD 152,924,000 for the same period in 2023[38]. - Gross profit for the same period was HKD 69,054,000, down from HKD 71,260,000, reflecting a decline of 3.1%[38]. - The net profit for the six months ended June 30, 2024, was HKD 30,277,000, a significant decrease of 41.0% compared to HKD 51,260,000 in 2023[38]. - Total comprehensive income for the period was HKD 19,357,000, compared to HKD 35,120,000 in 2023, indicating a decrease of 44.9%[52]. - The company reported a net loss of HKD 17,613,000 for the period, with total comprehensive income showing a loss of HKD 8,100,000[59]. Revenue Segments - The toy and gift manufacturing and sales segment generated revenue of approximately HKD 86.5 million, down from HKD 91 million in the previous year, with a gross margin of 42.2%, an increase from 40.1% due to reduced material costs[7]. - The revenue from the Chinese herbal medicine business for the period was approximately HKD 57 million, a decrease from HKD 61.9 million in 2023, representing a decline of about 4.6%[15]. - For the six months ended June 30, 2024, the group reported a total revenue of HKD 61,942,000, compared to HKD 56,950,000 for the same period in 2023, representing an increase of approximately 8.5%[77]. Cash Flow and Financial Position - As of June 30, 2024, the group's bank and cash balance was approximately HKD 98.5 million, compared to HKD 111.9 million as of December 31, 2023[17]. - The company's cash and cash equivalents decreased to HKD 98,529,000 as of June 30, 2024, down from HKD 111,867,000 at the beginning of the period, reflecting a net decrease of HKD 11,932,000[62]. - Operating cash outflow for the six months ended June 30, 2024, was HKD (47,557,000), compared to HKD (33,861,000) for the same period in 2023, indicating a worsening cash flow situation[62]. - The company's total assets less current liabilities increased to HKD 552,447,000 from HKD 492,932,000, an increase of 12.1%[57]. - The total assets of the group as of June 30, 2024, amounted to HKD 821,852,000, compared to HKD 170,281,000 as of June 30, 2023, reflecting a significant increase[78]. Debt and Liabilities - The group's debt as of June 30, 2024, was approximately HKD 135.9 million, down from HKD 141.8 million as of December 31, 2023[17]. - The capital debt ratio as of June 30, 2024, was 73.0%, a significant improvement from 89.1% as of December 31, 2023[18]. - Current liabilities decreased slightly to HKD 269,405,000 from HKD 277,349,000, a reduction of 2.5%[57]. - The company’s lease liabilities decreased to HKD 1,576,000 from HKD 1,846,000, indicating a reduction of approximately 14.6%[58]. - The deferred tax liabilities increased slightly to HKD 13,082,000 from HKD 12,927,000, reflecting a growth of about 1.2%[58]. Shareholder Actions - The group has not declared any interim dividend for the period, consistent with the previous year[5]. - The company issued 19,350,000 ordinary shares to creditors on May 17, 2024, to settle approximately HKD 19.2 million in debts[19]. - The company issued 9,210,000 ordinary shares to creditors on June 23, 2023, to settle approximately HKD 31,100,000 in debts[101]. - For the six months ending June 30, 2024, the company issued and allocated 150,000,000 ordinary shares after the conversion of convertible bonds amounting to HKD 45,000,000[102]. Operational Developments - The management anticipates delays in the commencement of high-end hotel and residential villa projects due to the global economic environment, now expected to start in January 2025[11]. - The group is adjusting its tea business model to enhance market competitiveness in response to increasing competition from online sales platforms[11]. - The company has plans for market expansion and new product development, focusing on the toy and herbal product sectors, although specific figures were not disclosed[64]. - The company is actively exploring potential mergers and acquisitions to enhance its market position and product offerings, although no specific targets were mentioned[64]. Employee and Operational Costs - Employee costs, including directors' remuneration, totaled HKD 21,914,000 for the six months ended June 30, 2024, compared to HKD 20,832,000 in the same period of 2023, marking an increase of approximately 5.2%[85]. - The group reported a depreciation expense of HKD 2,994,000 for property, plant, and equipment for the six months ended June 30, 2024, significantly higher than HKD 439,000 in the same period of 2023[85]. Inventory and Receivables - The company reported a significant increase in inventory, which rose to HKD 104,888,000 from HKD 87,910,000, reflecting a growth of 19.4%[57]. - Trade receivables increased to HKD 70,709,000 from HKD 57,229,000, marking an increase of 23.5%[57]. - Net trade receivables increased to HKD 70,709,000 as of June 30, 2024, from HKD 39,466,000 as of June 30, 2023, representing an increase of 79.3%[95]. - Trade receivables from customer contracts amounted to HKD 82,185,000 as of June 30, 2024, up from HKD 51,127,000 in 2023, reflecting a growth of 60.8%[95]. Audit and Compliance - The audit committee has reviewed the interim financial statements for the six months ended June 30, 2024, ensuring compliance with financial reporting standards[33].

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 143,434,000, a decrease of 6.5% from HKD 152,924,000 in the same period of 2023[1] - Gross profit for the same period was HKD 69,054,000, down from HKD 71,260,000, reflecting a gross margin of approximately 48.2%[1] - Net profit for the six months ended June 30, 2024, was HKD 30,277,000, a decline of 41.0% compared to HKD 51,260,000 in 2023[2] - Basic and diluted earnings per share for the period were HKD 18.54, down from HKD 39.21 in the previous year, representing a decrease of 52.8%[2] - The company reported a net profit of 17,613 thousand HKD for the six months ended June 30, 2024, compared to 36,415 thousand HKD for the same period in 2023, indicating a decrease of approximately 51.7%[22] - Basic earnings per share decreased to 18.54 HKD for the six months ended June 30, 2024, down from 39.21 HKD in the same period of 2023, reflecting a decline of about 52.8%[22] Assets and Liabilities - Total assets as of June 30, 2024, were HKD 552,447,000, an increase from HKD 492,932,000 as of December 31, 2023[5] - Cash and cash equivalents decreased to HKD 98,529,000 from HKD 111,867,000, indicating a reduction in liquidity[4] - Trade receivables increased to HKD 70,709,000 from HKD 57,229,000, reflecting a rise of 23.5%[4] - Inventory levels rose to HKD 104,888,000, up from HKD 87,910,000, indicating a 19.3% increase[4] - The company’s total liabilities increased to HKD 269,405,000 from HKD 277,349,000, showing a slight decrease in overall debt[5] - The group’s borrowings amounted to approximately HKD 135.9 million as of June 30, 2024, compared to HKD 141.8 million as of December 31, 2023[51] - The capital debt ratio as of June 30, 2024, was 73.0%, a decrease from 89.1% as of December 31, 2023[51] Segment Information - The company is primarily engaged in the manufacturing and sales of toys and gifts, development, processing, and trading of traditional Chinese medicine products, and investment in various potential businesses such as fruit planting, leisure, and culture[6] - The group has six major reportable segments, including exploration, toy and gift manufacturing and sales, fruit planting, leisure, culture, and traditional Chinese medicine[11] - The revenue for the toy and gift manufacturing and sales segment was approximately HKD 86.5 million, down from HKD 91 million in 2023, with a gross margin of 42.2%, an increase from 40.1% in 2023 due to reduced material costs[42] - The revenue from the Chinese herbal medicine business was approximately HKD 57 million, down from HKD 61.9 million in 2023[49] - The cultural business segment reported zero revenue for the current period, consistent with the previous year[48] Cash Flow and Investments - The company acquired property, plant, and equipment worth approximately 161,000 HKD during the reporting period, a significant increase from 4,000 HKD in the previous year[24] - The company plans to use approximately HKD 51,000,000 from the net proceeds of a share placement for repaying outstanding amounts of convertible bonds[37] - The company has acquired a 40% stake in the Zhongle Group, which holds operational rights to approximately 1,765.53 acres of forest land in Jiangxi Province[44] - The company is optimistic about future growth in the liquor industry, particularly in Huangjiu products, and has invested in Huangjiu since the end of 2016[47] - The company plans to develop rental properties in collaboration with Plantation Construction & Development Co Ltd, with a focus on residential and hotel developments, although the start date for high-end projects has been delayed to January 2025[45] Shareholder Information - The company did not declare any interim dividends for the current period, consistent with the previous year[21] - The company completed a share consolidation on April 28, 2023, where every five existing shares were consolidated into one share, changing the par value from HKD 0.01 to HKD 0.05[31] - Following the share consolidation on January 18, 2024, every two shares were consolidated into one share, increasing the par value to HKD 0.10[31] - The total issued and fully paid shares as of June 30, 2024, were 39,721,140,615, compared to 19,860,570,307 shares at the beginning of the year[29] - The company issued and allotted 9,210,000 ordinary shares to creditors to settle approximately HKD 31,100,000 of debts on June 23, 2023[32] - On May 17, 2024, the company issued and allotted 19,350,000 ordinary shares to creditors to settle approximately HKD 19,200,000 of debts[32] - As of June 30, 2024, 150,000,000 ordinary shares were issued and allotted to convertible bondholders after the conversion of HKD 45,000,000 of convertible bonds[32] Compliance and Governance - The financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards and the relevant listing rules, ensuring compliance with applicable disclosure requirements[7] - The management's estimates and judgments in preparing the financial statements are consistent with those applied in the annual consolidated financial statements for the year ending December 31, 2023[10] - The company has adopted the Standard Code for Directors' Securities Transactions as per the listing rules, confirming compliance by all directors during the reporting period[59] - The Audit Committee, consisting of independent non-executive directors, has reviewed the unaudited interim financial statements for the six months ending June 30, 2024[60] Employee and Operational Information - The company’s employee costs, including salaries and bonuses, amounted to 21,914 thousand HKD for the current period, an increase from 20,832 thousand HKD in the previous year[19] - The group employed 430 employees as of June 30, 2024, an increase from 387 employees as of December 31, 2023[55] - The group maintains a competitive compensation and benefits system, regularly reviewing it based on individual performance and industry practices[55] Risk and Future Outlook - The company is expected to continue its investment strategy in various sectors, including traditional Chinese medicine and cultural projects, to enhance growth potential[13] - The group is continuously reviewing its business to explore other profitable investment opportunities and aims to diversify its business and revenue base[53] - A subsidiary of the company, Marketing Resources Group, filed for voluntary bankruptcy under Chapter 7 of the U.S. Bankruptcy Code, but this is not expected to have a significant impact on the group's financial performance[38] - The company has not yet completed the transfer of 20% equity in Anhui Fulao due to non-cooperation from the management, and further actions will be taken if the transfer is not completed by January 2025[47] - The company is evaluating the impact of proposed arrangements on its operations and financial aspects[45] Miscellaneous - The financial results for the six months ending June 30, 2024, and June 30, 2023, are presented in thousands of Hong Kong dollars, ensuring clarity in financial reporting[12] - The financial statements do not include all information and disclosures required in the preparation of financial statements, suggesting that further details may be available in the annual report[9] - The group has not utilized any financial instruments for hedging purposes during the reporting period[51] - There were no purchases, redemptions, or sales of the company's securities by the company or any of its subsidiaries during the reporting period[61] - The interim results for 2024 have been published on the Hong Kong Stock Exchange website and the company's website, with reports to be sent to shareholders at the appropriate time[62] - The Board expresses gratitude to all shareholders, customers, suppliers, business partners, banks, professionals, and employees for their continued support[63]

Financial Performance - The company reported revenue of approximately HKD 383.9 million for the fiscal year ending December 31, 2023, a decrease of about 8.8% compared to HKD 420.9 million in 2022[3]. - Gross profit increased to HKD 165.8 million, representing a growth of 5.6% from HKD 157.0 million in the previous year[3]. - The profit attributable to shareholders was approximately HKD 37.2 million, a significant increase of about HKD 96.7 million from a loss of HKD 59.5 million in 2022, marking a 162.52% improvement[3]. - Basic earnings per share for the year were HKD 0.3906, compared to a loss of HKD 1.1744 per share in 2022, reflecting a 133.26% increase[3]. - The herbal medicine business generated revenue of approximately HKD 121,500,000, a decrease from HKD 127,900,000 in 2022[24]. - Revenue from North America was approximately HKD 262,000,000, down from HKD 292,000,000 in the previous year, accounting for about 68.2% of total revenue[24]. - Revenue from China (including Hong Kong) was approximately HKD 122,100,000, down from HKD 128,800,000, representing about 31.8% of total revenue[24]. - The company reported a significant increase in other income to HKD 8,458,000, up from HKD 1,244,000 in the previous year[149]. - Net profit for the year was HKD 65,701,000, compared to a loss of HKD 38,501,000 in 2022, indicating a significant turnaround[149]. - Total comprehensive income for the year was HKD 52,431,000, compared to a loss of HKD 58,662,000 in the previous year[151]. Assets and Liabilities - The total assets decreased by 12.46% to HKD 770.3 million from HKD 879.9 million in the previous year[3]. - The total equity increased by 19.29% to HKD 340.0 million, up from HKD 285.0 million in 2022[3]. - Non-current assets increased to HKD 454,819,000 in 2023 from HKD 486,629,000 in 2022, with property, plant, and equipment rising to HKD 107,820,000 from HKD 93,934,000[153]. - Current assets decreased to HKD 315,462,000 in 2023 from HKD 393,310,000 in 2022, primarily due to a reduction in other receivables[153]. - The company recorded a decrease in total liabilities from HKD 473,536,000 in 2022 to HKD 277,349,000 in 2023, showcasing a reduction in financial obligations[153]. - The company’s equity attributable to owners increased to HKD 214,208,000 in 2023 from HKD 185,734,000 in 2022, indicating growth in shareholder value[154]. Cash Flow and Financing - Operating cash flow for the year ended December 31, 2023, was HKD 27,543,000, a significant improvement from a cash outflow of HKD 146,700,000 in 2022[158]. - Net cash generated from financing activities was HKD 5,647,000, a decrease from HKD 43,416,000 in 2022[159]. - Total cash and cash equivalents at the end of 2023 increased to HKD 111,867,000 from HKD 99,058,000 at the beginning of the year[159]. - The company incurred interest expenses of HKD 27,068,000, down from HKD 46,812,000 in the previous year[158]. Investments and Acquisitions - The company is committed to developing planting facilities in China as part of its strategy to explore profitable investment opportunities[8]. - The acquisition of 49% equity in Jiangxi Jiua Food Co., Ltd. for HKD 45,750,000, with HKD 15,250,000 paid in shares and HKD 30,500,000 in convertible bonds, is still pending completion[33]. - The company recorded a loss of HKD 2.0 million from its investment in the fruit planting business, an improvement from a loss of HKD 5.8 million in 2022[16]. - Impairment losses on investments in associates amounted to HKD 34,314,000, with no such losses reported in 2022[149]. Administrative and Operational Expenses - The group’s administrative expenses increased by approximately 9.6% to about HKD 86,400,000 from HKD 78,800,000 in the previous year[26]. - Financial costs decreased by approximately 42.1% to HKD 27,100,000 from HKD 46,800,000 in the previous year[27]. - The total cost for retirement benefit plans was approximately HKD 2.765 million, an increase from about HKD 2.512 million in the previous year[66]. Corporate Governance and Compliance - The company is committed to achieving excellence in corporate governance and has complied with all applicable codes during the year[100]. - The board consists of three executive directors and three independent non-executive directors as of December 31, 2023[103]. - The independent non-executive directors are appointed for a designated term of two years, ensuring shareholder interests are protected[104]. - The company has not made appropriate insurance arrangements for directors since 2019 due to market availability issues[104]. - The audit committee held two meetings in 2023, with all members being independent non-executive directors[113]. Environmental and Social Responsibility - The company emphasizes environmental responsibility by implementing measures to reduce carbon footprint and energy consumption[89]. - The company has implemented various paper-saving measures to minimize waste and promote recycling[92]. - The group made charitable donations totaling approximately HKD 450,000, significantly up from HKD 28,000 in the previous year[64]. Shareholder Information - The company has proposed a share consolidation where every two existing shares of HKD 0.05 will be consolidated into one share of HKD 0.1, effective January 18, 2024[35]. - The public shareholding ratio exceeds 25% of the company's issued shares as of the report date[85]. - The company has no significant contingent liabilities or capital commitments as of December 31, 2023[38][39]. - No final dividend has been recommended for the year ending December 31, 2023[40]. Risk Management and Internal Controls - The company has engaged MOSS Valuation & Advisory Limited as an independent consultant to review the internal control system, covering financial, operational, and compliance controls[123]. - The risk management framework includes identifying significant risks, assessing their impact, and implementing necessary measures to manage those risks[124]. - The board has reviewed the risk management and internal control systems for the year ended December 31, 2023, and considers them effective[125].

Financial Performance - For the fiscal year ending December 31, 2023, total revenue was HKD 383,923,000, a decrease of 8.8% compared to HKD 420,904,000 in the previous year[3]. - Gross profit for the year was HKD 165,807,000, representing an increase of 5.4% from HKD 157,020,000 in the prior year[3]. - The net profit attributable to the company's shareholders was HKD 65,701,000, a significant recovery from a loss of HKD 38,501,000 in the previous year[4]. - Basic earnings per share for the year were HKD 19.53, compared to a loss per share of HKD 58.72 in the previous year[3]. - The total comprehensive income for the year was HKD 52,431,000, compared to a loss of HKD 58,662,000 in the previous year[4]. - Revenue from toy and gift sales for the year 2023 was HKD 262,377,000, compared to HKD 293,042,000 in 2022, representing a decrease of approximately 10.5%[25]. - Revenue from traditional Chinese medicine products for 2023 was HKD 121,546,000, down from HKD 127,862,000 in 2022, indicating a decline of about 4.3%[25]. - The company reported a net profit of HKD 65,701 for the year, compared to a net loss of HKD 38,501 in the previous year[30]. - The company reported a profit of HKD 37,213,000 for the year ending December 31, 2023, compared to a loss of HKD 59,521,000 in the previous year[47]. Expenses and Costs - Administrative expenses increased to HKD 86,381,000 from HKD 78,805,000, reflecting a rise of 9.9%[3]. - The company recognized an impairment loss of HKD 34,314,000 on investments in joint ventures, which was not present in the previous year[3]. - The company incurred financial costs of HKD 25,417 in 2023, down from HKD 45,840 in 2022, indicating a decrease of 44.7%[30]. - The company experienced a significant increase in administrative expenses related to legal and professional fees, totaling HKD 3,045,000, compared to HKD 3,806,000 in the previous year[44]. - The cost of goods sold for the year was HKD 21,827,000, reflecting an increase from HKD 2,778,000 in the previous year[44]. - Sales and distribution costs for the year were approximately HKD 37,300,000, a decrease from HKD 47,100,000 in 2022, primarily due to reduced salary costs in the toy division[96]. Assets and Liabilities - Total assets decreased from HKD 486,629,000 in 2022 to HKD 454,819,000 in 2023, a decline of approximately 6.5%[6]. - Non-current assets decreased from HKD 310,336,000 in 2022 to HKD 246,969,000 in 2023, a decrease of about 20.4%[6]. - Current assets increased from HKD 393,310,000 in 2022 to HKD 315,462,000 in 2023, a decrease of approximately 19.8%[6]. - Total liabilities decreased from HKD 473,536,000 in 2022 to HKD 277,349,000 in 2023, a reduction of approximately 41.4%[7]. - The company's equity attributable to owners increased from HKD 185,734,000 in 2022 to HKD 214,208,000 in 2023, an increase of about 15.4%[7]. - The company's total non-current liabilities decreased from HKD 121,395,000 in 2022 to HKD 152,956,000 in 2023, an increase of approximately 25.9%[7]. - The company's total equity remained stable at HKD 339,976,000 in 2023 compared to HKD 285,008,000 in 2022, reflecting a growth of about 19.3%[7]. - The company reported a significant increase in cash reserves, indicating improved liquidity and financial health[6]. Market and Strategic Focus - The company plans to focus on market expansion and new product development in the upcoming fiscal year[4]. - The group plans to expand its market presence in the tourism and tea-related product sectors, leveraging its strategic business segments[28]. - The company is focusing on cost management strategies to improve profitability moving forward[44]. - The group has a positive outlook on the growth of the liquor industry in China, particularly in Huangjiu products, and intends to invest further in this sector[88]. Compliance and Governance - The group has adopted new and revised Hong Kong Financial Reporting Standards effective from January 1, 2023, including HKFRS 17 on insurance contracts[13]. - The group anticipates that the application of the new and revised standards will not have a significant impact on its financial position and performance[16]. - The audit committee has reviewed the full-year performance announcement for the year ending December 31, 2023, ensuring compliance with financial reporting standards[123]. - The company has adhered to all applicable corporate governance code provisions, except for a specific deviation regarding independent non-executive directors' attendance at the annual general meeting[119]. Share Capital and Financing - The company completed a share consolidation on June 27, 2022, reducing the number of shares from 198,605,703,079 to 39,721,140,615[58]. - The company issued a total of 691,115,793 new ordinary shares at a price of HKD 0.205 per share to repay outstanding debts, raising approximately HKD 139,436,000 after transaction costs[65]. - The company implemented a share consolidation on April 28, 2023, where every five existing shares with a par value of HKD 0.01 were consolidated into one share with a par value of HKD 0.05[65]. - The company has outstanding convertible notes totaling HKD 92,000,000, which were issued as part of the acquisition of a 20% stake in Eagle Group[56]. - The company completed the placement of convertible bonds totaling up to HKD 45,000,000[108]. Employee and Operational Metrics - As of December 31, 2023, the company employed 387 staff, a decrease from 399 staff in 2022, indicating a reduction of approximately 3% in workforce size[117]. - The company plans to continue providing competitive compensation and benefits, with annual reviews based on individual performance and industry practices[117].

目錄 公司資料 2 管理層討論及分析 3 企業管治及其他資料 7 簡明綜合損益表 9 簡明綜合全面收入報表 10 簡明綜合財務狀況表 11 簡明綜合權益變動表 13 簡明綜合現金流量表 14 簡明綜合中期財務報表附註 15 公司 資料 執行董事： 張啟軍先生 （主席） 劉明卿先生 黎綺雯女士（於二零二三年四月十七日辭任） 獨立非執行董事： 王小寧先生 江俊榮先生（於二零二三年六月十五日退任） 陳雨鑫女士 魏鈺女士（於二零二三年六月十九日獲委任） 註冊辦事處 Sofia House 3rd Floor 48 Church Street Hamilton HM12 Bermuda 總辦事處及主要營業地點 香港 灣仔 駱克道315–321號 駱基中心 20樓E室 百慕達主要股份過戶登記處 Cohort Limited 3rd Floor, Sofia House 48 Church Street Hamilton HM12 Bermuda 香港股份過戶登記分處 卓佳登捷時有限公司 香港 夏慤道16號 遠東金融中心17樓 核數師 和信會計師事務所有限公司 香港九龍 尖沙咀東部 科學館道1號 康宏廣場 航天科技大廈 6 ...